Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
PRTA's Cash to Debt is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. PRTA: No Debt )
PRTA' s 10-Year Cash to Debt Range
Min: No Debt   Max: No Debt
Current: No Debt

Equity to Asset 0.96
PRTA's Equity to Asset is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. PRTA: 0.96 )
PRTA' s 10-Year Equity to Asset Range
Min: 0.91   Max: 0.98
Current: 0.96

0.91
0.98
Interest Coverage No Debt
PRTA's Interest Coverage is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. PRTA: No Debt )
PRTA' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

Z-Score: 30.29
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -1.43
PRTA's Operating margin (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. PRTA: -1.43 )
PRTA' s 10-Year Operating margin (%) Range
Min: -5980.33   Max: -978.44
Current: -1.43

-5980.33
-978.44
Net-margin (%) -3.36
PRTA's Net-margin (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. PRTA: -3.36 )
PRTA' s 10-Year Net-margin (%) Range
Min: -6064.5   Max: -1004.18
Current: -3.36

-6064.5
-1004.18
ROE (%) -0.54
PRTA's ROE (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. PRTA: -0.54 )
PRTA' s 10-Year ROE (%) Range
Min: -32.74   Max: -23.66
Current: -0.54

-32.74
-23.66
ROA (%) -0.51
PRTA's ROA (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. PRTA: -0.51 )
PRTA' s 10-Year ROA (%) Range
Min: -820.07   Max: -22.47
Current: -0.51

-820.07
-22.47
ROC (Joel Greenblatt) (%) -20.36
PRTA's ROC (Joel Greenblatt) (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. PRTA: -20.36 )
PRTA' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1220.45   Max: -1151.79
Current: -20.36

-1220.45
-1151.79
» PRTA's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

PRTA Guru Trades in Q3 2013

Vanguard Health Care Fund 249,624 sh (unchged)
» More
Q4 2013

PRTA Guru Trades in Q4 2013

Jim Simons 64,600 sh (New)
Vanguard Health Care Fund 902,524 sh (+261.55%)
» More
Q1 2014

PRTA Guru Trades in Q1 2014

Vanguard Health Care Fund 1,327,524 sh (+47.09%)
Jim Simons 79,112 sh (+22.46%)
» More
Q2 2014

PRTA Guru Trades in Q2 2014

Paul Tudor Jones 30,549 sh (New)
Leon Cooperman 100,000 sh (New)
Vanguard Health Care Fund 1,662,794 sh (+25.26%)
Jim Simons 51,900 sh (-34.4%)
» More
» Details

Insider Trades

Latest Guru Trades with PRTA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Leon Cooperman 2014-06-30 New Buy0.03%$18.73 - $39.62 $ 23-8%100000
Vanguard Health Care Fund 2014-06-30 Add 25.26%0.02%$18.73 - $39.62 $ 23-8%1662794
Vanguard Health Care Fund 2014-03-31 Add 47.09%0.04%$24.65 - $48.3 $ 23-28%1327524
Vanguard Health Care Fund 2013-12-31 Add 261.55%0.05%$19.93 - $29.04 $ 23-8%902524
Michael Price 2013-06-30 Sold Out 0.02%$6.6 - $13.71 $ 23147%0
Michael Price 2013-03-31 New Buy0.02%$5.84 - $7.33 $ 23261%21746
George Soros 2012-12-31 Sold Out $6.8 - $6.9 $ 23235%0
Michael Price 2012-12-31 Sold Out $6.8 - $6.9 $ 23235%0
Ray Dalio 2012-12-31 Sold Out $6.8 - $6.9 $ 23235%0
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 1.71
PRTA's P/B is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. PRTA: 1.71 )
PRTA' s 10-Year P/B Range
Min: 0.84   Max: 5.16
Current: 1.71

0.84
5.16
P/S 10.19
PRTA's P/S is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. PRTA: 10.19 )
PRTA' s 10-Year P/S Range
Min: 8.31   Max: 900.25
Current: 10.19

8.31
900.25
EV-to-EBIT -364.96
PRTA's EV-to-EBIT is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. PRTA: -364.96 )
PRTA' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: -364.96

Current Ratio 27.14
PRTA's Current Ratio is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. PRTA: 27.14 )
PRTA' s 10-Year Current Ratio Range
Min: 12.51   Max: 72.16
Current: 27.14

12.51
72.16
Quick Ratio 27.14
PRTA's Quick Ratio is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. PRTA: 27.14 )
PRTA' s 10-Year Quick Ratio Range
Min: 12.51   Max: 72.16
Current: 27.14

12.51
72.16

Valuation & Return

vs
industry
vs
history
Price/Net Cash 1.76
PRTA's Price/Net Cash is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. PRTA: 1.76 )
PRTA' s 10-Year Price/Net Cash Range
Min: 1.05   Max: 4.56
Current: 1.76

1.05
4.56
Price/Net Current Asset Value 1.75
PRTA's Price/Net Current Asset Value is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. PRTA: 1.75 )
PRTA' s 10-Year Price/Net Current Asset Value Range
Min: 1.04   Max: 4.51
Current: 1.75

1.04
4.51
Price/Tangible Book 1.71
PRTA's Price/Tangible Book is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. PRTA: 1.71 )
PRTA' s 10-Year Price/Tangible Book Range
Min: 1   Max: 4.35
Current: 1.71

1
4.35
Price/Median PS Value 0.24
PRTA's Price/Median PS Value is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. PRTA: 0.24 )
PRTA' s 10-Year Price/Median PS Value Range
Min: 0.23   Max: 14.34
Current: 0.24

0.23
14.34

Business Description

Industry: »
Compare: » details
Traded in other countries:0PT.Germany
Prothena Corporation PLC was incorporated in Ireland as a private limited company under the name Neotope Corporation Limited on September 26, 2012. On November1, 2012, it changed the name of the company to Prothena Corporation plc. It is a biotechnology company engaged in the discovery and development of novel antibodies for the potential treatment of an array of diseases that involve protein misfolding or cell adhesion. Its research and development pipeline includes three main therapeutic antibody programs: NEOD001 for the treatment of AL and AA Amyloidosis; PRX002 (formerly NEOD002) for the treatment of Parkinson's disease; and PRX003 for the potential treatment of inflammatory disease and metastatic cancers. Its pipeline also includes two late discovery stage programs: tau antibodies for potential treatment of Alzheimer's disease and antibodies for the potential treatment of type 2 diabetes. The competitors consist of major international companies, all of which are larger and have greater financial resources, technical staff, manufacturing, R&D and marketing capabilities. It also competes with smaller research companies and generic drug and biosimilar manufacturers. It is subject to significant regulation by international, national, state and local governmental regulatory agencies.
» More Articles for PRTA

Headlines

Articles On GuruFocus.com
Three Stocks With Massive Insider Buying Sep 03 2014 

More From Other Websites
Prothena Announces Presentation at Federation of European Physiological Societies 2014 Congress Aug 26 2014
Prothena Announces Presentation at Federation of European Physiological Societies 2014 Congress Aug 26 2014
Dr. Dale Schenk to Discuss Parkinson's Disease at 2014 Rejuvenation Biotechnology Conference Aug 18 2014
Dr. Dale Schenk to Discuss Parkinson's Disease at 2014 Rejuvenation Biotechnology Conference Aug 18 2014
PROTHENA CORP PLC Financials Aug 13 2014
PROTHENA CORP PLC Files SEC form 10-Q, Quarterly Report Aug 05 2014
PROTHENA CORP PLC Files SEC form 8-K, Results of Operations and Financial Condition Aug 04 2014
Prothena Reports Second Quarter 2014 Financial Results and R&D Progress Aug 04 2014
Prothena Reports Second Quarter 2014 Financial Results and R&D Progress Aug 04 2014
Initiation of Multiple Ascending Dose Phase 1 Study of PRX002 in Patients With Parkinson's Disease Jul 31 2014
Initiation of Multiple Ascending Dose Phase 1 Study of PRX002 in Patients With Parkinson's Disease Jul 31 2014
Coverage initiated on Prothena by Oppenheimer Jul 11 2014
Prothena Corporation (PRTA) Falls: Stock Goes Down 5.3% Jun 26 2014
PROTHENA CORP PLC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial... Jun 25 2014
BUZZ-U.S. Stocks on the Move-Schlumberger, Sequential, Broadcaster stocks Jun 25 2014
Prothena Announces Pricing of Public Offering of 4,750,000 Ordinary Shares Jun 25 2014
Prothena 4.75M share Secondary priced at $22.50 Jun 25 2014
Prothena Announces Pricing of Public Offering of 4,750,000 Ordinary Shares Jun 25 2014
Prothena Announces Proposed Offering of Ordinary Shares Jun 23 2014
Prothena Announces Proposed Offering of Ordinary Shares Jun 23 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK